Wesfarmers shares up for a short-week check with Bunnings in focus

Wesfarmers shares up for a short-week check with Bunnings in focus

June 8, 2026

SYDNEY, June 9, 2026, 04:04 (AEST)

Wesfarmers shares will face trading on Tuesday as the Australian Securities Exchange reopens, with the market watching a strategy update mid-week. Investors are looking for details on the company’s plan to put its Blackwoods and Workwear Group operations under the Bunnings banner.

ASX cash market didn’t trade Monday because of the King’s Birthday holiday, so Friday’s A$78.93 is still the last close ahead of the short week. No settlement on Monday. The equity market starts pre-open at 7:00 a.m. Sydney and regular trade begins around 10:00 a.m.

Wesfarmers ended up 0.41% Friday, though that wasn’t enough to pull it out of a rough week. Shares dropped roughly 1.1% since the May 29 close at A$79.79. The S&P/ASX 200 lost 0.70% on Friday to end at 8,625.10.

Wesfarmers’ latest corporate news was last week’s announcement that Blackwoods and Workwear Group will shift to Bunnings Group starting July 1. The company expects the move will enhance customer offers, push up sales and reduce costs. Financial results from the two businesses will be reported under Bunnings from the first half of fiscal 2027.

Wesfarmers Chief Financial Officer Anthony Gianotti said the company saw “a significant opportunity to leverage greater scale.” Bunnings Managing Director Mike Schneider said there should be “more choice, better product availability” for customers. Wesfarmers said it does not expect any material one-off costs from the move.

Wesfarmers will hold its Strategy Briefing Day in Sydney on June 10, with the event set to kick off at 8:30 a.m. AEST after presentation materials hit the ASX. The next known event is Wednesday. Full-year results are due Aug. 27.

A Friday filing said Kenneth Norman MacKenzie, who joined the board as a director on June 1, didn’t hold any shares himself but was indirectly interested in 8,148 fully paid ordinary shares via a family superannuation fund. These are the company’s standard listed shares.

Peer moves help explain the action, but Wesfarmers doesn’t line up directly with the supermarket names. Coles finished the day at A$22.21, adding 1.88%. Woolworths closed at A$35.69, up 1.22%. That’s more demand for food retail stocks than for Wesfarmers, which brings hardware, department stores, office supplies, health, chemicals, and industrials to the table.

Bunnings is a big piece of Wesfarmers’ numbers. Reuters calls Wesfarmers Australia’s largest non-food retailer, with Bunnings and Kmart key for the company. Investors often use its trading updates to get a sense of household spending, home improvement demand and small-business trends.

Short weeks can spark bigger moves than Friday’s quiet finish. Back in February, Wesfarmers topped first-half profit estimates. Shares still dropped after Wesfarmers flagged patchy consumer spending. CEO Rob Scott called inflation “one of the major challenges” in Australia, saying lower-income families “bear the brunt of it.” Reuters

Wesfarmers faces two tests on Tuesday and Wednesday: if shares can stay in the high-A$70s, and if the team will lay out details or dates for the Bunnings industrial move. Trade could be choppy after the holiday. The stock has a reason to move, but it still lacks conviction.

Stock Market Today

  • New Drug Apitegromab May Prevent Muscle Loss from Obesity GLP-1 Treatments
    June 8, 2026, 2:04 PM EDT. A new drug, apitegromab, shows promise in reducing muscle loss associated with GLP-1 obesity medications like Ozempic, Wegovy, and Mounjaro, which can cause unwanted muscle decline known as 'Ozempic butt.' In a six-month U.S. trial involving 102 adults, participants receiving apitegromab alongside Mounjaro retained 55% more muscle mass while still achieving fat loss. Muscle preservation is crucial since unlike fat, muscle is harder to regain. Apitegromab, administered via infusion, blocks a protein that triggers muscle breakdown and is under investigation for other muscle-related conditions. Experts urge caution, calling for larger and longer studies to confirm benefits such as improved strength and health outcomes. The treatments remain appetite suppressants and are not intended for short-term cosmetic use.